



Letter to the Editor

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer's disease



On March 27th, 2025 the Committee for Medical Product for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the refusal of the marketing authorization of donanemab for the treatment of early Alzheimer disease (AD), while on November 14th 2024 the same committee gave a positive recommendation for lecanemab for the same indication. Lecanemab was fully approved by the European Commission on the 15th of April 2025.

The rationale for the CHMP's opposing recommendation remains unclear. Lecanemab and donanemab are comparable in efficacy. In fact, the donanemab vs. placebo difference at 18 months was 0.67 points on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in the phase 3 clinical study TRAILBLAZER-ALZ 2, while it was 0.45 points in the lecanemab phase 3 study CLARITY-AD [1,2].

The CHMP argued that the risks of taking donanemab would not outweigh its benefit even after restriction to non-carriers of the Apolipoprotein E ϵ 4 (*APOE* ϵ 4) allele, who are at lowest risk of side effects. We acknowledge that the overall Amyloid Related Imaging Abnormality (ARIA) rate in TRAILBLAZER-ALZ 2 was higher than in CLARITY-AD [1,2]. However, given that ARIA are mostly asymptomatic and, if symptomatic, mostly of mild to moderate severity and transient, the very few cases of severe ARIA-E and macrohemorrhages with fatal outcome are the primary safety concerns. Of a total of 557 *APOE* ϵ 4 non-carriers in TRAILBLAZER-ALZ 2, one died of an ARIA-related intracerebral hemorrhage [1]. No further deaths in *APOE* ϵ 4 non-carriers in relation to ARIA have been reported neither in the initial TRAILBLAZER-ALZ study [3], nor in the TRAILBLAZER-ALZ 2 extension study [4], or in the recent TRAILBLAZER-ALZ 6 study [5]. The pooled number of *APOE* ϵ 4 non-carriers exposed to donanemab treatment across these studies is around 840, yielding a percentage of 0.1 % fatal cases ($n = 1$). This single case had superficial siderosis at baseline [1], which was not an exclusion criterion in TRAILBLAZER-ALZ 2, but should arguably be one in the label of donanemab as it is in the case of lecanemab. Hence, with baseline superficial siderosis and *APOE* ϵ 4 carrier status as exclusion criteria, there would have been most likely no treatment-related death in TRAILBLAZER-ALZ 2 and there was none in any of the other studies of the TRAILBLAZER-ALZ program.

In the TRAILBLAZER-ALZ 6 study, modified titration schemes were tested regarding ARIA frequency. One scheme with a lower starting dose but dose equivalence after three months showed similar pharmacokinetics to the standard dosing scheme of TRAILBLAZER-ALZ 2 in combination with lower ARIA rates in both, *APOE* ϵ 4 non-carriers and *APOE* ϵ 4 carrier [5]. TRAILBLAZER-ALZ 6 was designed without a placebo group so that efficacy against placebo cannot be derived from that study. The modified titration scheme of TRAILBLAZER-ALZ 6 is already used in treatment centers in the United States and is under regulatory review

by the United States Food and Drug Administration (FDA) and other regulatory bodies.

In addition, the CHMP concluded that the effect of donanemab on the primary outcome (integrated Alzheimer's Disease Rating Scale, iADRS) was smaller in the *APOE* ϵ 4 non-carrier subgroup than in the total group. In contrast, however, the data reported in the TRAILBLAZER-ALZ 2 supplement show greater efficacy of the donanemab in the *APOE* ϵ 4 non-carrier group [1]. It remains unclear on which analyses the CHMP conclusion is based.

The recommendation against donanemab also does not consider the benefits for patients and care partners related to the lower infusion frequency of donanemab compared with lecanemab (four weekly vs two weekly) and of the stopping rules (after 18 months or earlier after amyloid clearance with donanemab vs. continuous treatment with lecanemab). According to our clinical experience, the benefits for patients and care partners and important aspects in treatment decisions are not solely related to efficacy and safety, but also - to a significant extend - to lower treatment-related burden. Finally, having a choice between treatments not only benefits patients and care partners, but also health care systems, for example regarding pricing, and it serves the prospective development of treatments in real world care.

In summary, the authors consider the discrepancy between the positive recommendation for lecanemab and the negative recommendation against donanemab arbitrary, not consistent with the scientific evidence, and not to the benefit of patients and care partners. We hope that the CHMP reconsiders this decision and eventually provides a positive opinion in alignment with lecanemab, which may follow the same safety measures, including a Controlled Access Programme (CAP) and a Post Authorization Safety Study (PASS). We are strongly convinced that patients with early AD, care partners and health care systems will benefit from a choice between two alternative treatments with comparable efficacy and safety profiles, but different treatment regimes.

Potential conflicts of interest of individual authors regarding drug development in AD are detailed in the statement below.

Statement on AI

Generative AI or AI-assisted technology were not used in the preparation of this manuscript.

Declaration of competing interest

Frank Jessen: FJ has received grants from Roche Pharma and Roche Diagnostics; FJ has received consulting fees from Eli Lilly and Eisai; FJ has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Eli Lilly and Eisai; FJ has received payment for expert testimony from Eli Lilly and Eisai; FJ is Chairman of the EADC.

<https://doi.org/10.1016/j.tjpad.2025.100259>

Received 20 May 2025; Received in revised form 19 June 2025; Accepted 20 June 2025

Available online 9 July 2025

2274-5807/© 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>)

Javier Arbizu: JA has received research funding paid to University of Navarre Clinic from Siemens Healthineers, GE Healthcare, and PET tracer from Life Molecular Imaging; consultancy fees from Novartis and Eli Lilly; and received speaker honoraria from Biogen, Novartis, Life Molecular Imaging, Roche, Novo Nordisk, Siemens Healthineers, GE Healthcare, Zambon.

Mercé Boada: MB has received consulting fees from Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon, Novo Nordisk; MB has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Biogen, Grifols, Nutricia, Araclon Biotech, Servier, Novo Nordisk; MB participated in Data Safety Monitoring Board or Advisory of Board Grifols, Roche, Lilly, Araclon Biotech, Merck, Zambon, Biogen, Novo Nordisk, Bioiberica, Eisai, Servier, Schwabe Pharma, Lighthouse Pharma.

Mircea Balasa: No COI.

Karim Bennis has received grants to his institution from Acadia Pharmaceuticals, Alzheon Inc., Araclon Biotech S.L., AstraZeneca, Biogen, Bristol Myers Squibb, Eisai Inc., Eli Lilly, Genentech, Inc., GlaxoSmithKline, Hoffmann-La Roche, INmune Bio Inc., Janssen Research & Development, Medesis Parma, Merck Sharp & Dohme, Nestlé, Novartis Pharmaceuticals, Novo Nordisk, TauRx Therapeutics Ltd, UCB Biopharma.

Marina Boban has received grants from 4BrainFlames project, EU fund Research (managed by institution), Croatian Science Foundation Research (managed by institution).

Katharina Bürger: Honoraria from Eisai Germany, Lilly Germany, Roche; Travel support by Lilly Germany and Novo Nordisk.

Andrea Chincarin: No COI.

Annachiara Cagnin, AC received speaker honoraria from: PIAM, Eisai, GE, Lilly, Novo Nordisk, Roche.

Peter Paul De Deyn: consulted for Eisai, Biogen, and Perha Pharmaceuticals.

Emrah Düzel: Co-Founder and interim-CEO of neotiv, honoraria for advisory work talks from Roche, Lilly, Eisai, Biogen.

Sebastiaan Engelborghs: SE has received consulting fees from Biogen, Eisai (paid to institution), Icometrix (paid to institution), Janssen, Eli Lilly, Novartis (paid to institution). SE holds patent EP3452830B1 for an assay for the diagnosis of a neurological disease (licensed to ADX Neurosciences NV & Euroimmun Medizinische Labordiagnostika AG). SE is a member of SMB/SAB for EU-H2020 project RECAGE (unpaid) and of the DSMB of PRImus-AD (unpaid).

Michael Ewers: ME received research funding from Eli Lilly.

Lieza G. Exalto: PI at Brain Research Center, however not involved in lecanumab nor donanemab clinical trials.

Wiesje M. van der Flier: WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of phase 3 EVOKE/EVOKE+ studies (Novo Nordisk). WF is member of the steering committee of phase 3 Trontinemab study (Roche). All funding is paid to her institution.

WF is member of the steering committee of PAVE, and Think Brain Health. WF is chair of the Scientific Leadership Group of InRAD. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut.

Juan Fortea: JF reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zambón, Spanish Neurological Society, T21 Research Society, Lumind foundation, Jérôme-Lejeune Foundation, Alzheimer's Association, National Institutes of Health USA, and Instituto de Salud Carlos III. JF reports holding a patent for markers of synaptopathy in neurodegenerative

disease (licensed to ADx, EPI8382175.0). No other competing interests were reported.

Kristian Steen Frederiksen: KF has participated in advisory boards/consulted for Novo Nordisk, Roche Diagnostics, Eisai/Bioarctic, Eli Lilly (paid to institution), honoraria for lectures from Eisai/Bioarctic, Novo Nordisk, Eli Lilly (paid to institution), Editor-in-Chief, Alzheimer's Research & Therapy (Personal remuneration from Springer Nature).

Giovanni B Frisoni: GBF has received funding through the University of Geneva or Geneva University Hospitals: for IISs from ROCHE Pharmaceuticals OM Pharma EISAI Pharmaceuticals Biogen Pharmaceuticals and Novo Nordisk. He has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Biogen, Roche, Novo Nordisk, GE HealthCare. All through institution.

Lutz Frölich: Honoraria from Biogen, BioVie, Eisai, Eli Lilly, FOMF, Araclon/Grifols, Janssen Cilag, Medical Tribune, Medfora, Neurimmune, Noselab, Novo Nordisk, Roche, TauRX, Schwabe, StreamUp, Avanir/Otsuka, Pharmatrophix, Charité Berlin, Neuroscios, Vivoryon; Research support: Roche.

Alejandro J. Garza-Martinez: No COI.

Timo Grimmer: TG reported receiving consulting fees from Acumen, Advantage Ther, Alector, Anavex, Biogen, BMS; Cogthera, Eisai, Eli Lilly, Functional Neuromod., Grifols, Janssen, Neurimmune, Noselab, Novo Nordisk, Roche Diagnostics, and Roche Pharma; lecture fees from Anavex, Cogthera, Eisai, Eli Lilly, FEO, Grifols, Pfizer, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai and Eli Lilly.

Bernard Hanseeuw: consulted for Eisai, Biogen, and Roche.

Jakub Hort: consulted for Eisai, Biogen, Roche and Eli Lilly, speakers honoraria from Eli Lilly, Schwabe, stock options in Alzheon.

Adrian Ivanoiu: No COI.

Patrick G Kehoe: has received Research Grants from BRACE, Alzheimer's Brain Banks UK, the Bright Focus Foundation and R01AG074258 NIH (NIA); Payments made to the Institution for Biomedical related research projects on post mortem brain tissue unrelated to these drugs.

Sean P Kennelly: SPK has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Novo Nordisk, Eisai, Biogen and Nutricia; SPK has received support for attending meetings and/or travel from Roche and Nutricia.

Silke Kern: SK has served at scientific advisory boards, speaker and / or as consultant for Roche, Eli Lilly, Geras Solutions, Optoceutics, Biogen, Eisai, Merry Life, Triolab, Novo Nordisk and Bioarctic.

Stefan Klöppel: SK has received various research grants but not related data reported; SK has received consulting fees from OM Pharma (Participation dementia summit), SK has received payment or honoraria for lectures from OM Pharma (personal payment); participation on Advisory boards 2023: Advisory Board Alzheimer's Disease - Eisai Switzerland 2024: Advisory Board Rexulti AA - Lundbeck 2025: Advisory Board Alzheimer's Disease- Eisai (personal payment).

Lenka Krajčovičová: No COI.

Milica G. Kramberger: MGK has received consulting fees from Lilly; MGK has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly; MGK has participated in a Data Safety Monitoring Board or Advisory Board for Lilly.

Bernadette McGuinness: has received consulting fees from Biogen, Lilly, Eisai (payment made personally); has received payment or honoraria for Chair for Lilly sponsored event at British Geriatrics Society meeting 2024 (payment made personally).

Patrizia Mecocci: PM has received grants or contracts from HORIZON-JU-RIA Program AD-Riddle, Horizon 2020 Lethe; PM has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Piam, Angelini, Epitech; PM has participated in a Data Safety Monitoring Board or Advi-

sory Board Primus; PM is Treasurer Italian Academy of Geriatrics, Member Board of Directors SIGOT.

Timo Jan Oberstein: TJO received lecture honoraria from: Biogen, Lilly, Siemens Healthineers.

Pierre-Jean Ousset: has received consulting fees from Eli Lilly's, EISAI's, International Board and national board.

Claire Paquet: CP has received consulting fees from Eli Lilly's, EISAI's, Roche's, Novo Nordisk's, UCB's International Board and national board; CP has received payment or honoraria for lectures for Eli Lilly and EISAI; CP has received payment for expert testimony from Eli Lilly (national testimony with patient in April 2025).

Robert Perneczky: RP has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk.

Fabrizio Piazza: Consulting fees, advisory board fees, and educational activities, paid to the University of Milano Bicocca, with Alnylam Pharmaceuticals, Roche, Biogen, Alektor, Lilly, Araclon, Eisai. FP is the inventor, without ownership, of the amyloid-beta antibody ultrasensitive assay.

Domenico Plantone: DP received travel reimbursements from Fujirebio Italia srl.

Innocenzo Rainero: IR has received consulting honoraria from Eli Lilly.

Guillaume Sacco: has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from EISAI and Biogen, has received support for attending meetings and/or travel from Biogen and BMS.

Eric Salmon: Advisory Board for Biogen, Eisai, Will Pharma.

Isabel Santana: IS has received funding through the University of Coimbra: for IISs from FCT (National Agency for Research), ROCHE Pharmaceuticals OM Pharma Biogen Pharmaceuticals. She has received payment or honoraria for lectures, presentations, speakers or bureaus, from: Biogen, Lilly, EISAI, Novo Nordisk.

Nikolaos Scarmeas: Novo Nordisk - Local PI of recruiting site for multinational, multicenter industry sponsored phase III treatment trial for Alzheimer's disease - funding to institution.

Anja Schneider: Research Grant from Eisai (2020-2023), SAB for Biogen CELIA study, received honoraria from Eisai and Biogen.

Jonathan M Schott: JMS has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) and Alliance Medical; has consulted for Roche, Eli Lilly, Biogen, MSD and GE; and received royalties from Oxford University Press and Henry Stewart Talks. He is an NIHR Senior Investigator and Chief Medical Officer for Alzheimer's Research UK.

Eino Solje: E. Solje has served on the advisory board of Novartis, EISAI, Lilly and Roche, served as a consult for Novo Nordisk, BioArctic, EISAI, Lilly and Roche and received honoraria from for lectures from Lundbeck, BioArctic and Roche and travel support from Lilly.

Elka Stefanova: ES has received grants from AACSF-17-533520, IGPC-B-1262787, National Grant Republic of Serbia (451-03-66/2024-03/200110) (payment made to the institution); ES has received support for attending meetings and/or travel from Teva, Goodwill Pharma, Krka (payment made to the institution).

Elisabeth Stögmänn's institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Eisai, EU Horizon 2020, Austrian Research Promotion Agency).

Elisabeth Stögmänn's institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Biogen, Novo Nordisk and Roche Diagnostics.

Elisabeth Stögmänn received honoraria (consultations, lectures, speakers bureaus, educational events, advisory boards) from pharmaceutical companies: Biogen, Roche, Novo Nordisk, Eisai, Novartis, Sanofi and Lilly.

Elisabeth Stögmänn held leadership in scientific societies: Austrian Alzheimer Association.

Mélanie Strauss: consulted for Eisai.

Stanislav Sutovsky No COI.

Gunhild Waldemar: GW reported no conflicts of interest.

Bengt Winblad: BW serves as member of Scientific Advisory Boards (SABs) for Alzinova, Axon Neuroscience, Artery Therapeutics, Phanes Biotech and is a member of the DSMB for Primus-AD. BW has stocks in Artery Therapeutics and AlzeCure.

CRediT authorship contribution statement

Frank Jessen: Writing – review & editing, Writing – original draft, Conceptualization. **Javier Arbizu:** Writing – review & editing, Writing – original draft, Conceptualization. **Mercé Boada:** Writing – review & editing, Writing – original draft, Conceptualization. **Mircea Balasa:** Writing – review & editing, Writing – original draft, Conceptualization. **Karim Bennys:** Writing – review & editing, Data curation, Conceptualization. **Marina Boban:** Writing – review & editing, Writing – original draft, Conceptualization. **Katharina Bürger:** Writing – review & editing, Conceptualization. **Andrea Chincarini:** Writing – review & editing. **Annachiara Cagnin:** Writing – review & editing, Conceptualization. **Peter Paul De Deyn:** Writing – review & editing, Conceptualization. **Emrah Düzel:** Writing – review & editing, Conceptualization. **Sebastiaan Engelborghs:** Writing – review & editing, Conceptualization. **Michael Ewers:** Writing – review & editing, Conceptualization. **Lieza G. Exalto:** Writing – review & editing, Conceptualization. **Wiesje M. van der Flier:** Writing – review & editing, Conceptualization. **Juan Fortea:** Writing – review & editing, Conceptualization. **Kristian Steen Frederiksen:** Writing – review & editing, Conceptualization. **Giovanni B Frisoni:** Writing – review & editing, Conceptualization. **Lutz Frölich:** Writing – review & editing, Conceptualization. **Alejandro J. Garza-Martinez:** Writing – review & editing, Conceptualization. **Timo Grimmer:** Writing – review & editing, Conceptualization. **Bernard Hanseeuw:** Writing – review & editing, Conceptualization. **Jakub Hort:** Writing – review & editing, Conceptualization. **Adrian Ivanoiu:** Writing – review & editing, Conceptualization. **Patrick G Kehoe:** Writing – review & editing, Conceptualization. **Sean P Kennelly:** Writing – review & editing, Conceptualization. **Silke Kern:** Writing – review & editing, Conceptualization. **Stefan Klöppel:** Writing – review & editing, Conceptualization. **Lenka Krajčovičová:** Writing – review & editing, Conceptualization. **Milica G. Kramberger:** Writing – review & editing, Conceptualization. **Bernadette McGuinness:** Writing – review & editing, Conceptualization. **Patrizia Mecocci:** Writing – review & editing, Conceptualization. **Timo Jan Oberstein:** Writing – review & editing, Conceptualization. **Pierre-Jean Ousset:** Writing – review & editing, Conceptualization. **Claire Paquet:** Writing – review & editing, Conceptualization. **Robert Perneczky:** Writing – review & editing, Conceptualization. **Fabrizio Piazza:** Writing – review & editing, Conceptualization. **Domenico Plantone:** Writing – review & editing, Conceptualization. **Innocenzo Rainero:** Writing – review & editing, Conceptualization. **Guillaume Sacco:** Writing – review & editing, Conceptualization. **Eric Salmon:** Writing – review & editing, Conceptualization. **Isabel Santana:** Writing – review & editing, Conceptualization. **Nikolaos Scarmeas:** Writing – review & editing, Conceptualization. **Anja Schneider:** Writing – review & editing, Conceptualization. **Jonathan M Schott:** Writing – review & editing, Conceptualization. **Eino Solje:** Writing – review & editing, Conceptualization. **Elka Stefanova:** Writing – review & editing, Conceptualization. **Elisabeth Stögmänn:** Writing – review & editing, Conceptualization. **Mélanie Strauss:** Writing – review & editing, Conceptualization. **Stanislav Sutovsky:** Writing – review & editing, Conceptualization. **Gunhild Waldemar:** Writing – review & editing, Conceptualization. **Bengt Winblad:** Writing – review & editing, Conceptualization.

References

- [1] Sims JR, Zimmer JA, Evans CD, Lu M, Ardayio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM.

- TRAILBLAZER-ALZ 2 investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512–27. doi:10.1001/jama.2023.13239.
- [2] van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Izzarri M, Kramer LD, Iwatsubo T. Lecanemab in early Alzheimer's disease. *N Engl J Med* 2023;388(1):9–21. doi:10.1056/NEJMoa2212948.
- [3] Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in early Alzheimer's disease. *N Engl J Med* 2021;384(18):1691–704. doi:10.1056/NEJMoa2100708.
- [4] Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battouli C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR. Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. *JAMA Neurol* 2025:e250065. doi:10.1001/jamaneurol.2025.0065.
- [5] Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, Shcherbinin S, Andersen SW, Hauck PM, Engle SE, Brooks DA, Collins EC, Fox NC, Greenberg SM, Salloway S, Mintun MA, Sims JR. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. *Alzheimers Dement* 2025;21(4):e70062.

Frank Jessen*

Department of Psychiatry, University of Cologne, Medical Faculty,
Cologne, Germany
German Center for Neurodegenerative Diseases (DZNE), Bonn/Cologne,
Germany

Javier Arbizu

Department of Nuclear Medicine, University of Navarre Clinic,
Pamplona-Madrid, Spain
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain

Mercé Boada

Centro de Investigación Biomédica en Red en Enfermedades
Neurodegenerativas (CIBERNED), Spain
Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya,
Barcelona, Spain

Mircea Balasa

Centro de Investigación Biomédica en Red en Enfermedades
Neurodegenerativas (CIBERNED), Spain
Alzheimer's disease and other cognitive disorders Unit, Hospital Clínic de
Barcelona, Fundació Recerca Clínic Barcelona-IDIBAPS, Spain

Karim Bennys

Memory Research Ressources Center for Alzheimer's disease, Cognitive
Behavioral Neurology Unit, University Hospital Montpellier, France

Marina Boban

Department of Cognitive Neurology, University Hospital Centre Zagreb,
School of Medicine, University of Zagreb, Zagreb, Croatia

Katharina Bürger

Institute for Stroke and Dementia Research, University Hospital, LMU
Munich, Germany
German Center for Neurodegenerative Diseases (DZNE) Munich, Munich,
Germany

Andrea Chincarini

National Institute for Nuclear Physics (INFN), Genova, Italy

Annachiara Cagnin

Department of Neuroscience and Padua Neuroscience Center, University of
Padua, Italy

Peter Paul De Deyn

Laboratory of Neurochemistry and Behavior, Experimental Neurobiology
unit, Department of Biomedical Sciences, University of Antwerp and
Memory Clinic Antwerp, ZAS Antwerp, Belgium

Emrah Düzel

Institute of Cognitive Neurology and Dementia Research, Univ of
Magdeburg, Germany
German Center for Neurodegenerative Diseases (DZNE) Magdeburg,
Germany

Sebastiaan Engelborghs

Department of Neurology, Universitair Ziekenhuis Brussel and NEUR
Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel
(VUB), Brussels, Belgium
Department of Biomedical Sciences, University of Antwerp, Antwerp,
Belgium

Michael Ewers

Michael Ewers, Institute for Stroke and Dementia Research, University
Hospital, Ludwig Maximilian University Munich, Germany

Lieza G. Exalto

Department of Neurology, UMC Utrecht Brain Center, University Medical
Center Utrecht, Utrecht, Netherlands
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam,
Amsterdam UMC location VUmc, Amsterdam, the Netherlands
Julius Clinical, Zeist, the Netherlands

Wiesje M. van der Flier

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam,
Amsterdam UMC location VUmc, Amsterdam, the Netherlands
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam
UMC location VUmc, Amsterdam, the Netherlands

Juan Fortea

Sant Pau Memory Unit, Neurology Department, Institut d'Investigacions
Biomèdiques Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat
Autònoma de Barcelona, Barcelona, Spain

Kristian Steen Frederiksen

Danish Dementia Research Centre, Copenhagen University hospital
-Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen,
Denmark

Giovanni B Frisoni

Memory Center, Geneva University and University Hospitals, Geneva,
Switzerland

Lutz Frölich

Department of Geriatric Psychiatry, Central Institute of Mental Health,
Medical Faculty Mannheim, Heidelberg University, Germany

Alejandro J. Garza-Martinez

Servicio de Geriátría, Hospital Universitario Ramón y Cajal (IRICYS),
Madrid, Spain

Timo Grimmer

Department of Psychiatry and Psychotherapy, TUM University Hospital,
School of Medicine and Health, Technical University of Munich, Munich,
Germany

Bernard Hanseeuw

Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of
Neurosciences, Université catholique de Louvain, Brussels, Belgium

Jakub Hort

Department of Neurology, Charles University, Second Medical Faculty and
Motol University Hospital, Prague, Czech Republic

Adrian Ivanoiu

Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of
Neurosciences, Université catholique de Louvain, Brussels, Belgium

- Patrick G Kehoe
Cerebrovascular and Dementia Research Group, Bristol Medical School,
University of Bristol, Bristol, UK
- Sean P Kennelly
Tallaght Institute of Memory and Cognition, Tallaght University Hospital,
Dublin, Ireland
Department of Medical Gerontology, School of Medicine, Trinity College
Dublin, Ireland
- Silke Kern
Institute of Neuroscience and Physiology, Sahlgrenska Academy at the
University of Gothenburg, Sweden
Region Västra Götaland, Sahlgrenska University Hospital, Department of
Neuropsychiatry, Gothenburg, Sweden
- Stefan Klöppel
University Hospital of Old Age Psychiatry, University of Bern, Bern,
Switzerland
- Lenka Krajčovičová
Department of Neurology, Faculty of Medicine, Masaryk University and
Saint Anne's University Hospital, Brno, Czech Republic
- Milica G. Kramberger
Department of Neurology, University Medical Center, Medical faculty,
Ljubljana University of Ljubljana, Ljubljana, Slovenia
Karolinska Institutet, Department of Neurobiology, Care Sciences and
Society (NVS), Division of Clinical Geriatrics, Huddinge, Sweden
- Bernadette McGuinness
Centre for Public Health, Institute of Clinical Sciences B, Queen's
University Belfast, UK
- Patrizia Mecocci
Division of Gerontology and Geriatrics, Department of Medicine and
Surgery, University of Perugia, Italy
Division of Clinical Geriatrics, NVS Department, Karolinska Institutet
Stockholm, Sweden
- Timo Jan Oberstein
Department of Psychiatry and Psychotherapy, Uniklinikum Erlangen,
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen,
Germany
- Pierre-Jean Ousset
Institut Hospitalo Universitaire HealthAge, Alzheimer's Disease Research
and Clinical Center, Toulouse University Hospital, Toulouse, France
- Claire Paquet
Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal,
Université de Paris Cité - INSERM 1144, Faculty of Medicine, Paris, France
- Robert Perneczky
German Center for Neurodegenerative Diseases (DZNE) Munich, Munich,
Germany
Department of Psychiatry and Psychotherapy, University Hospital, LMU
Munich, Munich, Germany
Munich Cluster for Systems Neurology (SyNergy), 7 Munich, Germany
Ageing Epidemiology (AGE) Research Unit, School of Public Health,
Imperial College London, London, UK
Sheffield Institute for Translational Neuroscience (SITraN), University of
Sheffield, Sheffield, UK
- Fabrizio Piazza
CAA and AD Translational Research and Biomarkers Laboratory, School
of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
- Domenico Plantone
Department of Medicine, Surgery and Neuroscience, University of Siena,
Italy
- Innocenzo Rainero
Memory Clinic, Department of Neuroscience "Rita Levi Montalcini",
University of Torino, Italy
- Guillaume Sacco
Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Clinique
Gériatrique du cerveau et du mouvement, Centre Mémoire de Ressources et
de Recherche, Nice, France
Université Côte d'Azur, INSERM, CNRS, IPMC, Equipe AlzPark, Nice,
France
- Eric Salmon
Memory Clinic, Liege University Hospital, Liege, Belgium
- Isabel Santana
Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Department of Neurology, Hospital da Universidade de Coimbra, ULS de
Coimbra, Coimbra, Portugal
- Nikolaos Scarmeas
1st department of Neurology, Medical School, National and Kapodistrian
University of Athens, Aiginitio Hospital, Athens, Greece
Department of Neurology, Columbia University, New York, NY, USA
- Anja Schneider
Department of Old Age Psychiatry and Cognitive Disorders, University
Hospital Bonn, Bonn, Germany
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- Jonathan M Schott
Dementia Research Centre, Queen Square Institute of Neurology, London,
UK
UK Dementia Research Institute, UK
- Eino Solje
Institute of Clinical Medicine - Neurology, University of Eastern Finland,
Kuopio, Finland
Neuro Center - Neurology, Kuopio University Hospital, Kuopio, Finland
- Elka Stefanova
University of Belgrade, Faculty of Medicine, Serbia
- Elisabeth Stögmänn
Department of Neurology, Medical University of Vienna, Austria
- Mélanie Strauss
Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles
(H.U.B.), CUB Hôpital Erasme, Service de Neurologie, Bruxelles, Belgium
- Stanislav Sutovsky
1st Department of Neurology, Faculty of Medicine, Comenius University
and University Hospital, Bratislava, Slovakia
- Gunhild Waldemar
Danish Dementia Research Centre, Department of Neurology, Copenhagen
University Hospital - Rigshospitalet, Denmark
Department of Clinical Medicine, University of Copenhagen, Denmark
- Bengt Winblad
Div of Neurogeriatrics, Dept NVS, Karolinska Institutet, Stockholm and
Theme Inflammation & Aging, Karolinska University Hospital, Huddinge,
Sweden

*Corresponding author at: Department of Psychiatry, University of
Cologne, Kerpener Strasse 62, 50937 Cologne, Germany.
E-mail address: frank.jessen@uk-koeln.de (F. Jessen)

Revised 19 June 2025